Pharmacotherapeutic profile of venlafaxine

European Psychiatry

Volumn 12, Issue SUPPL. 4, 1997, Pages 285s-294s

  Preskorn, S ^a  

^a University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

Antidepressants; Clinical pharmacology; Serotonin noradrenaline uptake inhibitors; Venlafaxine

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZATROPINE; CHLORPHENIRAMINE; CIMETIDINE; CITALOPRAM; CYTOCHROME P450; DESIPRAMINE; DOPAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROTRANSMITTER; NEUROTRANSMITTER UPTAKE INHIBITOR; NORADRENALIN; OMEPRAZOLE; PAROXETINE; PRAZOSIN; QUINIDINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFAPHENAZOLE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; YOHIMBINE;

ANTICHOLINERGIC EFFECT; BINDING AFFINITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUSTAINED RELEASE PREPARATION;

EID: 0030807212     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(97)83307-X     Document Type: Article

References (29)

1. Altamura AC, Montgomery SA, Wernicke JF. The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry 1988;153(suppl 3): 109-12
2. Baron BM, Ogden A-M, Siegel BW, Stegeman J, Ursillo RC, Dudley MW. Rapid down regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988;154:125-34
3. Beasley CM Jr, Bosomworth JC, Wernicke JF. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26:18-24
4. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-9
5. Burke MJ, Silkey B, Preskorn SH. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry 1994;55(suppl A):42-52
6. Clerc GE, Ruimy P, Verdeau-Paillés J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-43
7. Cunningham LA, Borison RL, Carman JS et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106
8. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-65
9. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71
10. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989;25:71-9
11. Ereshefsky L, Alfaro CL, Lam YWF. Treating depression: Potential drug interactions. Psychiatric Annuals 1997;17: 244-58
12. Guelfi JD, White C, Hackett D et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-8
13. Moyer JA, Muth EA, Haskins JT et al. In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030 and Wy-45,881 (abstract). Soc Neurosci 1984;10:261
14. Muth EA, Haskins JT, Moyer JA, Husbands GEM et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7
15. Muth EA, Moyer JA, Haskins JT et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-9
16. Nelson JC, Mazure CM, Bowers MB, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-7
17. Otton SV, Ball SE, Cheung SW et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41:149-56
18. Preskorn SH. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994a; 9(suppl 3):13-19
19. Preskorn SH. Outpatient Management of Depression. Professional Communications Inc. Caddo, 1994b
20. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994C;55:(suppl A):6-22
21. Preskorn SH. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Caddo: Professional Communications Inc, 1996
22. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(1):1-21
23. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52(suppl):23-33
24. Preskorn SH, Janicak PG, Davis JM, Ayd FJ. Advances in the pharmacotherapy of depressive disorders. In: Janicak PG, Davis JM, Preskorn SH, Ayd FJ, eds. Principles and Practice of Psychopharmacotherapy. Williams and Wilkins: Baltimore, 1995;1-24
25. Rudolph R, Entsuah R, Derivan A. A low relapse rate confirms the long-term efficacy of venlafaxine in the treatment of major depression (abstract). Neuropsychopharmacology 1994;10(suppl):105
26. Rudolph RL, Fabre L, Feighner J, Rickels K. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1997 (in press)
27. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55: 104-8
28. Shrivastava RK, Cohn C, Crowder J, Davidson J et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994;14:322-9
29. Shad MU, Carmichael CA, Preskorn SH, Horst WE. Prevalence of polypharmacy in different clinical settings and its relation to drug-drug interactions. San Diego: Annual Meeting of the American Psychiatric Association, 1997